Document Detail


Sugar substitutes: Health controversy over perceived benefits.
MedLine Citation:
PMID:  22025850     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
Sugar is an inseparable part of the food we consume. But too much sugar is not ideal for our teeth and waistline. There have been some controversial suggestions that excessive sugar may play an important role in certain degenerative diseases. So artificial sweeteners or artificially sweetened products continue to attract consumers. A sugar substitute (artificial sweetener) is a food additive that duplicates the effect of sugar in taste, but usually has less food energy. Besides its benefits, animal studies have convincingly proven that artificial sweeteners cause weight gain, brain tumors, bladder cancer and many other health hazards. Some kind of health related side effects including carcinogenicity are also noted in humans. A large number of studies have been carried out on these substances with conclusions ranging from "safe under all conditions" to "unsafe at any dose". Scientists are divided in their views on the issue of artificial sweetener safety. In scientific as well as in lay publications, supporting studies are often widely referenced while the opposing results are de-emphasized or dismissed. So this review aims to explore the health controversy over perceived benefits of sugar substitutes.
Authors:
Kirtida R Tandel
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of pharmacology & pharmacotherapeutics     Volume:  2     ISSN:  0976-5018     ISO Abbreviation:  J Pharmacol Pharmacother     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-10-25     Completed Date:  2011-11-10     Revised Date:  2014-01-13    
Medline Journal Info:
Nlm Unique ID:  101552113     Medline TA:  J Pharmacol Pharmacother     Country:  India    
Other Details:
Languages:  eng     Pagination:  236-43     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus.
Next Document:  Impact of chronic disease assistance program on the retail pharmacy sector: A retrospective study.